To further investigate the implication of FADD expression in the outcome of precursor T-cell neoplasms, we performed additional analyses of the clinic-pathological data associated to 264 patients (TARGET cohort), considering FADD levels. This evidence concerns the gene FADD and T-cell and NK-cell neoplasm.